Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Genprex Said The Combination Of Reqorsa Gene Therapy (Quaratusugene Ozeplasmid) And An ALK Inhibitor Led To Longer Survival In The Mouse Model Of ALK-EML4 Positive Non-small Cell Lung Cancer

Author: Benzinga Newsdesk | October 28, 2025 06:14am

Reqorsa Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer
Combining REQORSA with Alectinib Further Increased Apoptosis and Improved Treatment Outcomes in a Mouse Model

Posted In: GNPX